Product Description
von Willebrand Factor Antibody [3E2D10] | 33-225 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Amino acids 845-949 were used as the immunogen for this vWF antibody.
Research Area: Cancer, Stem Cell
Tested Application: WB, Flow, IHC, IF
Application: Flow Cytometry: 0.5-1 ug/million cells
IF: 0.5-1 ug/ml
WB: 0.5-1.0 ug/ml
IHC (FFPE) : 0.5-1.0 ug/ml for 30 minutes at RT (1)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the vWF antibody to be titered up or down for optimal performance.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G purified vWF antibody
Clonality: Monoclonal
Clone: 3E2D10
Isotype: IgG1, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: VWF, Coagulation factor VIII VWF, F8VWF, VWD, Von Willebrand factor
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: von Willebrand Factor is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This vWF antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi’s sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.